Radiopharmaceutical developer Neoprobe has signed a definitive acquisition agreement to purchase the outstanding shares of Israel-based blood-flow technology vendor Biosonix by the end of the year. Neoprobe of Dublin, OH, will issue 9.7 million shares of its common stock to Biosonix shareholders at closing, with an additional 2.1 million shares to be provided upon the satisfaction of a milestone event involving Biosonix product development, according to Neoprobe.
By AuntMinnie.com staff writersDecember 11, 2001
Related Reading
Neoprobe revenue drops in third quarter, November 5, 2001
Biosonix gets CE mark for FlowGuard, October 4, 2001
Neoprobe to buy Biosonix, September 7, 2001Neoprobe revenues, net income slide, August 8, 2001
CZT supplier highlights small-FOV gamma camera, June 27, 2001
Copyright © 2001 AuntMinnie.com